Acute Myeloid Leukemia Clinical Trials in Valencia
17 recruitingValencia, Spain
Showing 1–17 of 17 trials
Recruiting
Phase 1Phase 2
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute Leukemia+2 more
Syndax Pharmaceuticals447 enrolled57 locationsNCT04065399
Recruiting
Phase 2Phase 3
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+1 more
Taiho Oncology, Inc.316 enrolled73 locationsNCT04256317
Recruiting
Phase 3
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Acute Myeloid LeukemiaRelapse/Recurrence
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS339 enrolled37 locationsNCT06713837
Recruiting
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS4,000 enrolled38 locationsNCT06459024
Recruiting
Phase 1
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.27 enrolled22 locationsNCT04953910
Recruiting
Phase 1
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.18 enrolled21 locationsNCT04953897
Recruiting
Phase 1Phase 2
A Study of BGB-11417 in Participants With Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
BeiGene260 enrolled46 locationsNCT04771130
Recruiting
Phase 1
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
Acute Myeloid Leukemias
Syndax Pharmaceuticals76 enrolled46 locationsNCT06226571
Recruiting
Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Adult Acute Myeloid Leukemia
Priothera SAS366 enrolled108 locationsNCT05429632
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemias
Janssen Research & Development, LLC400 enrolled101 locationsNCT04811560
Recruiting
Phase 3
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
PedAL BCU, LLC98 enrolled89 locationsNCT05183035
Recruiting
Phase 1Phase 2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Acute Myeloid LeukemiaNon-Hodgkin LymphomaMultiple Myeloma+3 more
CellCentric Ltd.250 enrolled39 locationsNCT04068597
Recruiting
Phase 1Phase 2
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Solid TumorsAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+6 more
Incyte Biosciences International Sàrl70 enrolled25 locationsNCT03934372
Recruiting
Phase 1
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute LeukemiaAML+9 more
Kura Oncology, Inc.171 enrolled44 locationsNCT06001788
Recruiting
Phase 1Phase 2
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdvanced Malignant Neoplasm+4 more
Kura Oncology, Inc.263 enrolled56 locationsNCT04067336
Recruiting
Phase 3
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland227 enrolled119 locationsNCT07075016
Recruiting
Phase 2
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Acute Myeloid Leukemia
Ryvu Therapeutics SA98 enrolled37 locationsNCT06191263